Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
申请人:Bristol-Myers Squibb Company
公开号:US09308236B2
公开(公告)日:2016-04-12
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Use of t-butyl 4-diethylphosphono-3-oxobutanethioate for tetramic acid synthesis: Total synthesis of the plasmodial pigment fuligorubin A
作者:Steven V. Ley、Stephen C. Smith、Peter R. Woodward
DOI:10.1016/s0040-4039(00)82204-2
日期:1988.1
A short, efficient synthesis of the yellow slime mould pigment fuligorubin A (1) has been achieved using coupling of t-butyl 4-diethylphosphono-3-oxobutanethioate with deca-2,4,6,8-tetraenal and subsequent substitution with a glutamic acid derivative followed by Dieckmann cyclisation.
MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS
申请人:Bristol-Myers Squibb Company
公开号:US20140294898A1
公开(公告)日:2014-10-02
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Macrocyclic Inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 Protein/Protein Interactions
申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US20160340391A1
公开(公告)日:2016-11-24
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.